Clinical trial · Interventional
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by the formation of cysts in the kidneys, causing gradual renal function-loss. Previous studies have shown that, reduced glomerular filtration rate (GFR) and renal plasma flow (RPF) play a role in the progression of renal disease in ADPKD. Tolvaptan is a vasopressin 2 antagonist, which seems to reduce the growth of total kidney volume (TKV) and the decline in e-GFR in ADPKD. The mechanism is not fully understood and could, at least partly, be caused by stimulation of the renal blood flow. The purpose of this trial is to investigate if tolvaptan´s improve renal blood flow and glomerular filtration in ADPKD, in a randomized, cross-over, double-blind, placebo-controlled study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Kidney, Autosomal Dominant | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Drug | — | UNRESOLVED |
| Tolvaptan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Tolvaptan
- description
- Drug: Tolvaptan 1 tablet before renography
- interventionNames
- Drug: Tolvaptan
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo 1 tablet before renography
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Renal plasma flow (RPF)
- timeFrame
- Two hours after trial medicine intake
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Diagnosis with ADPKD * Informed consent * Contraception for fertile women Exclusion Criteria: * Renal transplantation * Operation in the kidney * Diabetes mellitus * Neoplastic conditions * Pregnancy, nursing * Unwillingness to participate * eGFR \> 30 * Intolerance towards tolvaptan * Alcohol or medical abuse, * BP \>\>170/110 blood pressure despite regulation
References
Publications (0)
Data not yet available